Niacin for Cholesterol

Verdict: Improves lipid numbers, not heart outcomes

At gram-level doses niacin clearly moves your cholesterol numbers in the right direction, but high-quality trials show it does not lower the risk of heart attack, stroke, or death, so it is no longer recommended as a cholesterol treatment.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

The grade is Weak (C) because the evidence splits sharply between two different questions. On the lipid panel itself, the data are strong and consistent: a meta-analysis in type 2 diabetes found high-dose niacin raised HDL-C by 0.27 mmol/L and cut LDL-C and triglycerides by 0.25 and 0.39 mmol/L (PMID 25306426), and a review documented HDL-C up 21-31% with LDL-C and triglycerides down sharply (PMID 26210594). Mayo Clinic agrees the numbers move, citing roughly +30% HDL and -25% triglycerides.

The problem is that better numbers did not translate into fewer cardiovascular events. A 2019 systematic review of 35,760 participants found no benefit for cardiovascular mortality (RR 0.98) or coronary mortality (RR 0.90) (PMID 30977858). An earlier meta-analysis had suggested benefit, but that finding reversed once the large HPS2-THRIVE trial was added (PMID 23265337). This surrogate-versus-outcome gap is exactly why the score stays low despite real effects on lab values.

Regulators and clinicians have stepped back accordingly. The US FDA concluded the evidence no longer supports the idea that raising HDL or lowering triglycerides cuts cardiovascular risk in statin-treated patients, and withdrew the statin-combination indication in 2016. Mayo Clinic states niacin is not linked to lower rates of death, heart attack, or stroke in most people, and the UK NHS warns that high doses cause flushing and can lead to liver damage. The lipid-active doses are drug-territory, not what ordinary B-vitamin supplements provide.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable

Raw score 0.48

← counter-evidence / ineffectiveeffective / strong evidence →

Final grade

C · Published with Warning

Confidence

79%

Broadly consistent

Evidence level

Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive

L5 Clinical bodiesAuthoritative stance

0.41

L2 PubMedPrimary literature

0.45

L3 MechanismPlausibility

0.45

L1 ExamineGlobal benchmark

0.50

L11 AI re-checkIndependent read

0.80

Against Mixed Supports

▸View the full decision path (audit trail)

compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.48
tier_from_score — 依分數區間映射至 tier letter
apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
tier_strict_requirement_check — Tier 條件達標，未降階
detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Niacin in the Treatment of Hyperlipidemias in Light of New Clinical Trials: Has Niacin Lost its Place?

PMID: 26210594 2015 Other

Finding: Earlier trials documented robust lipid-panel改善 with niacin — HDL-C +21–31%, LDL-C -12–43%, triglycerides -26–31% — yet the review concludes the favourable surrogate-marker effect did not translate into cardiovascular event reduction once HPS2-THRIVE data were included.

Effect size: HDL-C +21–31%; LDL-C -12–43%; TG -26–31% (lipid numbers); no incremental CV benefit

View on PubMed

Effect of niacin on lipids and glucose in patients with type 2 diabetes: A meta-analysis of randomized, controlled clinical trials

PMID: 25306426 2015 統合分析

Finding: In type 2 diabetes patients niacin significantly raised HDL-C (+0.27 mmol/L), lowered LDL-C (-0.25 mmol/L) and lowered triglycerides (-0.39 mmol/L); long-term treatment raised fasting glucose (+0.085 mmol/L), so glucose monitoring is advised.

Effect size: HDL-C +0.27 mmol/L; LDL-C -0.25 mmol/L; TG -0.39 mmol/L; FPG +0.085 mmol/L

View on PubMed

Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis

PMID: 30977858 2019 統合分析 n = 35,760

Finding: Across 35,760 participants niacin showed no association with CVD mortality (RR 0.98, 95% CI 0.90–1.07) or CHD mortality (RR 0.90, 95% CI 0.76–1.06); the authors note most trials over 60 years measured surrogate lipid markers (HDL-C, LDL-C, TG) rather than hard outcomes, and flushing caused 25–40% discontinuation.

🟢 High quality Effect size: CVD mortality RR 0.98 (NS); CHD mortality RR 0.90 (NS)

View on PubMed

The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression

PMID: 23265337 2013 系統性回顧

Finding: This pre-HPS2-THRIVE meta-regression reported a significant reduction in composite cardiovascular and major CHD events with niacin; the host review notes that adding HPS2-THRIVE data later made the outcome conclusion substantially different (no benefit).

🟠 Limited quality Effect size: Significant CV event reduction (pre-HPS2-THRIVE); reversed once HPS2-THRIVE included

View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA

Cautious

the totality of the scientific evidence no longer supports the conclusion that a drug-induced reduction in triglyceride levels and/or increase in HDL-cholesterol levels in statin-treated patients results in a reduction in the risk of cardiovascular events source↗

L4b EU EFSA

Neutral

L4c UK NHS

Cautious

Taking high doses of nicotinic acid supplements can cause skin flushes. Taking high doses for a long time could lead to liver damage. ... Taking 17mg or less of nicotinic acid supplements a day, or 500mg or less of nicotinamide supplements a day, is unlikely to cause any harm. source↗

L4d TW TFDA / 衛福部

Neutral

菸鹼酸（包括菸鹼醯胺）屬第（八）類營養添加劑；用於錠狀、膠囊狀食品，每日食用限量以菸鹼素當量（N.E.）計不得超過 100 毫克。 source↗

L4e WHO

Neutral

Pellagra is treated with at least 300 mg of nicotinamide in oral divided doses daily for 3-4 weeks. Nicotinamide is recommended in preference to nicotinic acid (niacin) because it does not cause the flushing reaction. source↗

L5a NIH Office of Dietary Supplements

Cautious

L5b Mayo Clinic

Neutral

Niacin can lower triglycerides by 25% and raise HDL cholesterol by more than 30%. Despite niacin's ability to lower triglycerides and raise HDL cholesterol, research suggests that niacin therapy isn't linked to lower rates of death, heart attack or stroke in most people. source↗

L5c Cleveland Clinic

Neutral

L5d Harvard Health

Against

L5e Specialty Society (condition-mapped)

Cautious

✓PMID 100% verifiedevery citation checked via NCBI Entrez

🔬4 PubMed studiesindependently re-checked by multiple sub-agents

engine_version: v1.0 claim_id: CLM-COND-cholesterol-INT-niacin-001 繁體中文版 →